Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophi…
Biotechnology
US, Cambridge [HQ]
Lobbying Analysis
Lobbying · US Senate · Influence
Solid Biosciences Inc. has no lobbying expenses in our database.
History
Download| FY | Quarter | Expense For Lobby Disclosure | LDA Reference |
|---|---|---|---|
| No data |